dc.contributor.author |
Mrkela, Miran |
|
dc.contributor.author |
Tan, Shu-Li |
|
dc.contributor.author |
Taylor, G-M |
|
dc.contributor.author |
Gorrie, Cathy |
|
dc.contributor.author |
Green, Colin |
|
dc.contributor.author |
O'Carroll, Simon |
|
dc.coverage.spatial |
Queenstown, New Zealand |
|
dc.date.accessioned |
2021-06-04T03:05:21Z |
|
dc.date.available |
2021-06-04T03:05:21Z |
|
dc.date.issued |
2018-8-27 |
|
dc.identifier.citation |
Australasian Winter Conference on Brain Research AWCBR 2018, Queenstown, New Zealand. Editors: Hillman, Kristin. Proceedings of the 36th International Australasian Winter Conference on Brain Research. AWCBR - University of Otago. 33-33. 27 Aug 2018 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/55230 |
|
dc.description.abstract |
Spinal cord injury has been shown to induce an ongoing chronic inflammatory state, beginning as soon as a few weeks post injury and sometimes persisting for years. This state of ongoing inflammation creates an inhibitory milieu around the injury site resulting in the inhibition of axonal repair/regeneration and the onset of neuropathic pain in patients.
Connexin 43 hemichannels have been shown to be a major component in perpetuating this inflammatory state. Tonabersat is a validated hemichannel modulating drug which we have used to block these
Connexin 43 hemichannels in an effort to reduce the chronic inflammatory environment.
To date there are no therapies available which successfully limit this state of chronic inflammation. In order to investigate whether Tonabersat reduces chronic inflammation, we utilised a chronic contusion spinal cord injury rat model. Following initial contusion, the animals were given a 6 week period for the chronic inflammation to manifest, after which
Tonabersat was administered orally for a 4 week period.
The effect of Tonabersat on astrogliosis and microgliosis was examined. The treated animals showed a reduction in the level of astrocyte staining compared to nontreated animals. Additionally we saw a reduced presence of microglia around the lesion between treated and non-treated animals. These data indicate that connexin hemichannel modulation may be able to alleviate chronic spinal cord inflammation and potentially improve long-term outcomes. |
|
dc.relation.ispartof |
Australasian Winter Conference on Brain Research |
|
dc.relation.ispartofseries |
Proceedings of the International Australasian Winter Conference on Brain Research |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.title |
Analysis of M1 and M2 Macrophage Markers in Assessing Drug Effects on Chronic Inflammation |
|
dc.type |
Conference Item |
|
dc.date.updated |
2021-05-21T03:16:29Z |
|
dc.rights.holder |
Copyright: The author |
en |
pubs.author-url |
https://web.archive.org/web/20201130202457if_/https://www.otago.ac.nz/awcbr/proceedings/otago694586.pdf |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Conference Paper |
|
pubs.elements-id |
853305 |
|